Methylnaltrexone's Effect on Cholestasis in Trauma Patients

Area of Science:

• Medical Science
• Gastroenterology
• Trauma Care

Background:

• Opioid-induced cholestasis in hospitalized patients can lead to severe complications like acalculous cholecystitis, sepsis, and death.
• Trauma patients are particularly vulnerable to opioid side effects due to prolonged pain management needs.

Purpose of the Study:

• To evaluate the outcomes of trauma patients treated with methylnaltrexone, focusing on the incidence of cholestasis.
• To compare the clinical outcomes, including length of stay and mortality, between trauma patients who received methylnaltrexone and a matched control group.

Main Methods:

• Retrospective cohort study at a level 1 trauma center.
• Inclusion of trauma patients aged 18+ from January 2018 to January 2024, excluding those with specific pre-existing conditions.
• Comparison of a methylnaltrexone treatment group (n=56) with a matched control group (n=56) using SPSS, analyzing demographic data, length of stay, ICU stay, ventilator days, and mortality.

Main Results:

• No statistically significant difference in the incidence of cholestasis (1.8% in both groups) between the methylnaltrexone and control groups.
• Methylnaltrexone group had significantly longer hospital stays (13 vs. 1 day, p < .001) and ICU stays (4 vs. 0 days, p < .001).
• Higher mortality was observed in the methylnaltrexone group (p = .044), with 5 deaths compared to 1 in the control group.

Conclusions:

• Patients receiving methylnaltrexone were generally sicker, evidenced by longer hospitalizations and increased mortality.
• Methylnaltrexone did not demonstrate a significant impact on the incidence of cholestasis or acalculous cholecystitis in this trauma patient cohort.
• Further research with larger sample sizes is recommended to explore potential causal relationships and refine treatment strategies.